Watching Your Language: FDA Ad Division Objects To User-Friendly Efficacy Claims With Jargon-y Risk Info
Executive Summary
FDA expects drug advertisements to use the same level of language to convey both safety and efficacy information, according to a pair of letters from the Division of Drug Marketing, Advertising and Communications
You may also be interested in...
Convenience Claims, Squinty Risk Info For Arbor's Nitro Spray Draw FDA Letter
Professional sales aid and DTC brochure for Nitrolingual Pumpspray claim the product is superior to tablets without substantial evidence, DDMAC says.
Novartis Advertising Cited By FDA For Fifth Time In Less Than A Year
CBER's Advertising and Promotional Labeling Branch says that Novartis improperly expanded the age range for its Fluvirin influenza vaccine.
FDA Objects To Claims Based On Low-Quality Evidence In DTC Ads
FDA's Division of Drug Marketing, Advertising and Communications recently used a series of untitled letters to emphasize that the evidence used to make claims in a promotion piece must be of sufficient quality